Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|July 27, 2015
The Lessons of High Cost Specialty Drug Product Launches
Author(s)Davy James, Managing Editor
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Advertisement
David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
3
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
4
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
5